Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACH: Precision Medicine and Adoptive Cellular Therapy for Recurrent Neuroblastoma and Newly Diagnosed DIPG
NCT04837547Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Sep 2021
- Primary completion
- Sep 2027
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of TTRNA-xALT in neuroblastoma and diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by University of Florida. Primary endpoint: Dose Limiting Toxicities at 2 years. Started Sep 2021; status: recruiting.
02
Drugs
TTRNA-xALT
03
Conditions
neuroblastomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04837547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837547.